Literature DB >> 29649815

Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation.

Klaus-Peter Dieckmann1,2, Hanna Richter-Simonsen1, Magdalena Kulejewski1, Raphael Ikogho1, Henrik Zecha1, Petra Anheuser1, Uwe Pichlmeier3, Hendrik Isbarn4.   

Abstract

INTRODUCTION: Clinical characteristics of testicular germ cell tumours (GCTs) apparently change over time, and some vary geographically. The aim of this study is to document the clinical profile of contemporary GCT patients. PATIENTS AND METHODS: Four hundred twenty-two Caucasian GCT-patients treated in one German centre during 2000-2017, were analysed in terms of patient-age, laterality, histology, tumour-size, clinical stages (CS), pathological (pT)-stages and serum biomarker expression. The results were analysed descriptively and compared with the literature.
RESULTS: Median age was 36 years and 60.2% had seminoma. Βeta-human chorionic gonadotropin was expressed in 37.9% and alpha Fetoprotein in 25.6%. CS1 presenting stage was 66.6% of all GCT patients, 79.1% in seminoma, and 47.6% in nonseminoma. Tumour size was significantly associated with pT-stages and CS. Patients >50 years had significantly more seminoma (77.6%) than younger ones (57.9%). Comparison with literature data revealed a shifting towards higher age, lower CS, higher proportion of seminoma and striking differences of characteristics among geographic regions.
CONCLUSIONS: A typical contemporary clinical profile of testicular GCTs is presented in this study. Median age, relative incidence of seminoma and proportion of CS1 appear to be increasing over time. Striking differences among ethnic groups regarding the characteristics of GCT require further investigation. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Clinical staging; Germ cell tumour; Nonseminoma; Seminoma; Tumour markers; Tumour size

Mesh:

Year:  2018        PMID: 29649815      PMCID: PMC6039091          DOI: 10.1159/000488284

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  59 in total

1.  Assessing the size and stage of testicular germ cell tumours: 1984-2003.

Authors:  Jeetesh M Bhardwa; Tom Powles; Dan Berney; Suhail Baithun; Vinod H Nargund; R Tim D Oliver
Journal:  BJU Int       Date:  2005-10       Impact factor: 5.588

Review 2.  [TNM classification of testicular tumors. Definitions and prerequisites for correct application].

Authors:  C Wittekind
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

3.  A statistical review of malignant testicular tumours based on the experience of the Ontario Cancer Foundation Clinics, 1938-1961.

Authors:  E N MacKay; A H Sellers
Journal:  Can Med Assoc J       Date:  1966-04-23       Impact factor: 8.262

4.  Obscure etiology, unusual disparity: the epidemiology of testicular cancer in New Zealand.

Authors:  Jason K Gurney; Diana Sarfati; James Stanley
Journal:  Cancer Causes Control       Date:  2015-02-17       Impact factor: 2.506

Review 5.  Testicular cancer update.

Authors:  Nabil Adra; Lawrence H Einhorn
Journal:  Clin Adv Hematol Oncol       Date:  2017-05

6.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 7.  Testicular cancer in young Norwegians.

Authors:  S D Fosså; N Aass; O Kaalhus
Journal:  J Surg Oncol       Date:  1988-09       Impact factor: 3.454

8.  Mortality of Testicular Cancer in East and West Germany 20 Years after Reunification: A Gap Not Closed Yet.

Authors:  Andreas Stang; Freddie Bray; Klaus-Peter Dieckmann; Joannie Lortet-Tieulent; Carsten Rusner
Journal:  Urol Int       Date:  2015-05-07       Impact factor: 2.089

9.  During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival.

Authors:  Julia Heinzelbecker; Michaela Katzmarzik; Christel Weiss; Lutz Trojan; Axel Haecker
Journal:  Int Braz J Urol       Date:  2013 Jan-Feb       Impact factor: 1.541

10.  Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association.

Authors:  Tsuneharu Miki; Kazumi Kamoi; Hiroyuki Fujimoto; Hiro-omi Kanayama; Chikara Ohyama; Kazuhiro Suzuki; Hiroyuki Nishiyama; Masatoshi Eto; Seiji Naito; Tomoharu Fukumori; Yoshinobu Kubota; Satoru Takahashi; Kazuya Mikami; Yukio Homma
Journal:  Int J Urol       Date:  2014-04-13       Impact factor: 3.369

View more
  16 in total

1.  [Knowledge and early detection of testicular germ cell cancer among adolescents and young adults].

Authors:  P Anheuser; S Mühlstädt; P Fornara; J Steffens; K P Dieckmann; J Kranz
Journal:  Urologe A       Date:  2019-11       Impact factor: 0.639

2.  Metastatic Testicular Seminoma in a Patient With Down Syndrome Presenting As Extensive Deep Venous Thrombosis.

Authors:  Meredith Hengy; Amita Hinge; James P Purtell; Kathren Shango; Joshua Collins
Journal:  Cureus       Date:  2022-09-11

Review 3.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

Review 4.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

5.  Supraclavicular left neck mass: an unusual presentation of metastatic testicular cancer in two older men.

Authors:  Chinnoi Law; Zainab AlshiekhAli; Nicholas Taylor; David Howlett
Journal:  BMJ Case Rep       Date:  2020-04-22

6.  Primary Chemotherapy in a 47-Year-Old Patient with Giant Ulcerative and Necrotizing Nonseminomatous Testicular Germ Cell Tumor.

Authors:  Sophia Stock; Julian Marcon; Michael Chaloupka; Armin Becker; Wolfgang G Kunz; Steffen Ormanns; Theresia Pichler; Friederike H A Mumm; Julian W Holch; Lars H Lindner
Journal:  Case Rep Oncol       Date:  2021-04-15

7.  Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Authors:  Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge
Journal:  J Clin Oncol       Date:  2019-03-15       Impact factor: 44.544

8.  Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up-A Copenhagen Experience.

Authors:  Nina Mørup; Ewa Rajpert-De Meyts; Anders Juul; Gedske Daugaard; Kristian Almstrup
Journal:  Cancers (Basel)       Date:  2020-03-23       Impact factor: 6.639

9.  Overexpression of p75NTR in Human Seminoma: A New Biomarker?

Authors:  Anna Perri; Vittoria Rago; Rocco Malivindi; Lorenza Maltese; Danilo Lofaro; Emanuela Alessandra Greco; Luigi Tucci; Renzo Bonofiglio; Margherita Vergine; Sandro La Vignera; Eusebio Chiefari; Antonio Brunetti; Antonio Aversa
Journal:  Life (Basel)       Date:  2021-06-29

10.  Diagnostic performance of microRNAs in testicular germ cell tumors: a systematic review and meta-analysis.

Authors:  Xi-Yi Zhao; Yu-Lu Gao; Dan-Feng Li; Hong-Chao Liu; Rui-Fang Zhu; Chang-Tai Zhu
Journal:  Aging (Albany NY)       Date:  2021-08-03       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.